AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Allianz Technology Trust PLC

Share Issue/Capital Change May 2, 2019

4747_rns_2019-05-02_ceb6b756-4b74-4826-ad2d-5787c4380081.html

Share Issue/Capital Change

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 9380X

Allianz Technology Trust PLC

02 May 2019

Allianz Technology Trust plc (the "Company")

LEI: 549300OMDPMJU23SSH75

2 May 2019

In accordance with the block listing application announced on 22 June 2018, the Company has today issued 70,000 new ordinary shares of 25p each from the Company's general block listing facility at a price of 1618p per share. This represents a premium of 1.01% to the current net asset value. These shares are issued under the new waiver of pre-emption rights authorised by shareholders at the General Meeting on 23rd July 2018 and rank pari passu with existing shares in issue.

Following this issue, the Company has the ability to issue 428,212 ordinary shares under its block listing facility. As a result of this allotment, the total number of ordinary shares in issue now stands at 33,974,668.The company no longer holds any shares in treasury.

The above figure (33,974,668) may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.

Enquiries:

Eleanor Emuss

Company Secretary

Tel: 020 3246 7405

2 May 2019

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

IOEFMGGKDZLGLZM

Talk to a Data Expert

Have a question? We'll get back to you promptly.